Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal

International Archives of Allergy and Immunology

Volumn 157, Issue 3, 2012, Pages 215-225

  Valent, Peter ^a,b   Akin, Cem ^c   Arock, Michel ^d   Brockow, Knut ^e   Butterfield, Joseph H ^f   Carter, Melody C ^g   Castells, Mariana ^c   Escribano, Luis ^h   Hartmann, Karin ⁱ   Lieberman, Philip ^j   Nedoszytko, Boguslaw ^k   Orfao, Alberto ^l   Schwartz, Lawrence B ^m   Sotlar, Karl ⁿ   Sperr, Wolfgang R ^a   Triggiani, Massimo ^o   Valenta, Rudolf ^a   Horny, Hans Peter ^p   Metcalfe, Dean D ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Ecole Normale Superieure de Cachan   (France)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MAYO CLINIC   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j University of Tennessee Campbell Clinic   (United States)

^k MEDICAL UNIVERSITY OF GDANSK   (Poland)

^l Centro de Investigacion del Cancer   (Spain)

^m VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p Institute of Pathology   (Germany)

more..

Author keywords

Allergy; Anaphylaxis; Mast cell activation syndrome; Mast cells; Tryptase

Indexed keywords

ANTIHISTAMINIC AGENT; CHEMOKINE; CROMOGLYCATE DISODIUM; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GLUCOCORTICOID; HISTAMINE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE INHIBITOR; STEM CELL FACTOR RECEPTOR; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE;

ALLERGY; ANGIONEUROTIC EDEMA; ARTICLE; CELL HYPERPLASIA; CONSENSUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; MAST CELL; MAST CELL ACTIVATION SYNDROME; MAST CELL LEUKEMIA; MASTOCYTOSIS; MEDIATOR RELEASE; MEDICAL RESEARCH; METABOLITE; NASAL PRURITUS; NOMENCLATURE; NOSE CONGESTION; PATHOGENESIS; PATIENT ATTITUDE; PRIORITY JOURNAL; PRURITUS; SWELLING; SYMPTOMATOLOGY; THROAT DISEASE; URTICARIA; WHEEZING;

ATTITUDE TO HEALTH; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAST CELLS; MASTOCYTOSIS; TRYPTASES;

EID: 79959598455     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000328760     Document Type: Article

References (58)

1. Rivera J, Gilfillan AM: Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006; 117: 1214-1225. (Pubitemid 43795719)
2. Metcalfe DD: Mast cells and mastocytosis. Blood 2008; 112: 946-956.
3. Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008; 8: 478-486. (Pubitemid 351733419)
4. Austen KF: Systemic anaphylaxis in the human being. N Engl J Med 1974; 291: 661-664.
5. Serafin WE, Austen KF: Mediators of immediate hypersensitivity reactions. N Engl J Med 1987; 317: 30-34. (Pubitemid 17093294)
6. Simons FE: Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161-S181.
7. Webb LM, Lieberman P: Anaphylaxis: A review of 601 cases. Ann Allergy Asthma Immunol 2006; 97: 39-43. (Pubitemid 44156335)
8. Lieberman P: Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 316-320.
9. Peavy RD, Metcalfe DD: Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 310-315.
10. Golden DB: What is anaphylaxis? Curr Opin Allergy Clin Immunol 2007; 7: 331-336. (Pubitemid 47052021)
11. Finkelman FD, Boyce JA, Vercelli D, Rothenberg ME: Key advances in mechanisms of asthma, allergy, and immunology in 2009. J Allergy Clin Immunol 2010; 125: 312-318.
12. Metcalfe DD: Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc 2000; 21: 21-24.
13. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, et al: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125: 1269.e.2-1278.e2.
14. González de Olano D, de la Hoz Caballer B, Núñez López R, Sánchez Muñoz L, Cuevas Agustín M, Diéguez MC, Alvarez Twose I, Castells MC, Escribano Mora L: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: A study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37: 1547-1555. (Pubitemid 47460231)
15. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, Castellani L, Bonetto C, Frattini F, Dama A, Martinelli G, Chilosi M, Senna G, Pizzolo G, Zanotti R: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123: 680-686.
16. Metcalfe DD, Schwartz LB: Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123: 687-688.
17. Donker ML, Bakker NA, Jaspers WJ, Verhage AH: Two patients with osteoporosis: Initial presentation of systemic mastocytosis. J Bone Miner Metab 2008; 26: 199-202. (Pubitemid 351317126)
18. Valent P, Akin C, Escribano L, Fodinger M, Hartman K, Metcalfe DD, et al: Standards and standardization in mastocytosis: Consensus statement on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453. (Pubitemid 46817344)
19. Ruëff F, Dugas-Breit S, Przybilla B: Stinging Hymenoptera and mastocytosis. Curr Opin Allergy Clin Immunol 2009; 9: 338-342.
20. Akin C: Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthma Rep 2010; 10: 34-38.
21. Akin C, Valent P, Metcalfe DD: Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126: 1099-1104.
22. Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, Van der Linden PW: Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis. J Clin Immunol 1994; 14: 190-204. (Pubitemid 24182179)
23. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96: 2702-2710.
24. Schwartz LB, Irani AM: Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14: 641-657. (Pubitemid 30436938)
25. Morel AM, Delaage MA: Immunoanalysis of histamine through a novel chemical derivatization. J Allergy Clin Immunol 1988; 82: 646-654. (Pubitemid 18261018)
26. Awad JA, Morrow JD, Roberts LJ: Detection of the major urinary metabolite of prostaglandin D 2 in the circulation: Demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994; 93: 817-824. (Pubitemid 24154096)
27. Hogan AD, Schwartz LB: Markers of mast cell degranulation. Methods 1997; 13: 43-52. (Pubitemid 27453065)
28. Di Lorenzo G, Pacor ML, Vignola AM, Profita M, Esposito-Pellitteri M, Biasi D, Corrocher R, Caruso C: Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy 2002; 57: 1180-1186. (Pubitemid 36071864)
29. van Toorenenbergen AW, Oranje AP: Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta 2005; 359: 72-77. (Pubitemid 41116298)
30. Butterfield JH, Weiler CR: Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D 2 production. Int Arch Allergy Immunol 2008; 147: 338-343.
31. van der Donk EM, Blok W, Kok PT, Bruijnzeel PL: Leukotriene C 4 formation by enriched human basophil preparations from normal and asthmatic subjects. Prostaglandins Leukot Essent Fatty Acids 1991; 44: 11-17.
32. Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, Valent P: Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142: 158-164. (Pubitemid 46095928)
33. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD: Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis. Blood 2007; 110: 2331-2333. (Pubitemid 47523152)
34. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001; 25: 603-625. (Pubitemid 32506768)
35. Horny HP, Valent P: Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543-551. (Pubitemid 32506761)
36. Arock M, Valent P: Pathogenesis, classification and treatment of mastocytosis: State of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497-516.
37. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836. (Pubitemid 38608590)
38. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al: Second symposium on the definition and management of anaphylaxis: Summary report -Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397. (Pubitemid 43190153)
39. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, et al: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183: 2681-2686. (Pubitemid 26192378)
40. Jordan JH, Schernthaner GH, Fritsche-Polanz R, Sperr WR, Födinger M, Chott A, et al: Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): Histopathologic and morphologic evaluation with special reference to recently established SM-criteria. Leuk Lymphoma 2002; 43: 575-582. (Pubitemid 34232925)
41. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM: Mastocytosis; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues.Lyon, IARC Press, 2001, pp 291-302.
42. Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P, Bain BJ: Mastocytosis (mast cell disease); in Swerdlow, SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds): World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 54-63.
43. Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP, Bennett JM: Myelomastocytic overlap syndromes: Biology, criteria, and relationship to mastocytosis. Leuk Res 2001; 25: 595-602. (Pubitemid 32506767)
44. Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K: Myelomastocytic leukemia: Myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002; 3: 90-94. (Pubitemid 34555535)
45. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, et al: Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98: 2200-2209.
46. Arredondo AR, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A, et al: Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. Am J Hematol 2010; 85: 600-606.
47. Castells MC, Irani AM, Schwartz LB: Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 138: 2184-2189. (Pubitemid 17046271)
48. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F, et al: Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001; 98: 2580-2583.
49. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372. (Pubitemid 44497521)
50. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al: Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130: 804-815.
51. Daley T, Metcalfe DD, Akin C: Association of the Q576R polymorphism in the interleukin-4 receptor α -chain with indolent mastocytosis limited to the skin. Blood 2001; 98: 880-882.
52. Nedoszytko B, Niedoszytko M, Lange M, van Doormaal J, Glen J, Zablotna M, et al: Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy 2009; 64: 287-294.
53. Murphy S, Kelly HW: Cromolyn sodium: A review of mechanisms and clinical use in asthma. Drug Intell Clin Pharm 1987; 21: 22-35. (Pubitemid 17228198)
54. Chin KW, Garriga MM, Metcalfe DD: The histamine content of oriental foods. Food Chem Toxicol 1989; 27: 283-287. (Pubitemid 19181174)
55. Maintz L, Novak N: Histamine and histamine intolerance. Am J Clin Nutr 2007; 85: 1185-1196. (Pubitemid 46740458)
56. Schwelberger HG: Histamine intolerance: A metabolic disease? Inflamm Res 2010; 59: 219-221.
57. Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, et al: The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr 2004; 116: 647-651. (Pubitemid 39518122)
58. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al: Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358: 28-35.